mBos TKA System vs CORI in 2026

mBos TKA System

The Monogram mBos TKA System is a robotic total-knee-arthroplasty platform from Monogram Technologies, a Zimmer Biomet subsidiary since October 2025. It is the autonomy-boundary case of DEPLOY's surgical cluster: unlike the AI-augmented, surgeon-controlled systems (Stryker Mako, Smith+Nephew CORI, Zimmer Biomet ROSA), where the surgeon makes the cuts, the cleared mBos is semi-autonomous, with a robotic arm (built on a KUKA arm) executing the bone cuts itself under AI control within a surgeon-approved, patient-specific CT-based plan and active surgeon supervision.

There is no consumer price: it is pre-commercial enterprise surgical equipment that has not sold any units. Several verified-vs-claimed cap-flags matter. It received FDA 510(k) clearance on March 17, 2025, but the exact K-number could not be independently verified, and the 'semi-autonomous' characterization is sourced to Zimmer Biomet and trade coverage rather than the FDA letter (Monogram's own clearance release described it more softly as robotic-assisted TKA).

A separate fully-autonomous, hands-free, saw-based version is not FDA cleared and remains in development, targeted around late 2027 or 2028; its first live-patient procedure (July 26, 2025, Ahmedabad, India) was under an India CDSCO 102-procedure investigation, not US FDA, a single index case with no verified peer-reviewed outcomes. Monogram was founded by orthopedic surgeon Dr.

Doug Unis (chief medical officer and founder, not CEO; the pre-acquisition CEO was Benjamin Sexson) and was acquired by Zimmer Biomet at about $168M enterprise value plus contingent value rights, with commercialization alongside Zimmer Biomet implants targeted for early 2027. The registry records it at research maturity: cleared but pre-commercial, with its headline fully-autonomous capability still in development.

CORI

Smith+Nephew's CORI Surgical System is a compact, surgeon-controlled handheld robotics platform for orthopedic knee surgery and the handheld, imageless archetype of the orthopedic sub-cohort. It is imageless (no pre-operative CT or MRI): the surgeon paints the joint surface intra-operatively to build a 3D bone model, then uses a handheld robotic bur whose cutting speed and exposure are robotically controlled to the surgical plan, with optical navigation.

Its small footprint positions it for ambulatory surgery centers and outpatient ORs. It is AI-augmented but surgeon-controlled, not autonomous. A critical verified-vs-claimed distinction aggregators routinely blur: CORI's robotic burring is cleared for the knee only (total, partial/unicompartmental, and revision knee); its hip capability is navigation-only (RI.HIP NAVIGATION, cleared January 2022), not robotic burring.

Made by Smith+Nephew (LSE: SN; NYSE: SNN). As enterprise B2B surgical equipment, there is no consumer price.